Despite Vaccine, Shingles Keeps Striking Elderly Patients

The virus that causes childhood chickenpox doesn’t fade away with youth. It haunts people later in life in the form of shingles, a disease affecting more than one million Americans a year that can cause excruciating pain, lesions, vision impairment and other severe symptoms.

As The New York Times reports, about five years ago the U.S Food and Drug Administration thought help was on the way when it approved a vaccine called Zostavax. Research has shown it can reduce the outbreak of shingles by 51 percent and, for patients with the disease, it can alleviate symptoms.

But so far there is little progress in beating back shingles.

Merck, maker of the vaccine, has been unable to quickly crank up production. Although the company shipped 2 million doses in the first half of this year, more than in any previous year, Zostavax still is in scant supply.

The resulting shortages have kept the company from aggressively marketing the vaccine, and have stalled public health campaigns to raise awareness of the disease.

As of the most recent federal survey in 2009, the vaccine was given to only 10 percent of adults 60 and older, the group most vulnerable. Adults, overall, face a one in three chance of developing shingles.

“It really, really has been frustrating,” said Dr. Rafael Harpaz, an epidemiologist at the federal Centers for Disease Control and Prevention. “There hasn’t been a single year since the vaccine was licensed in 2006 that there’s been no problem with supply.”

According to Merck, the vaccine is made with a live attenuated virus that has proved difficult to grow in bulk, and which also is needed to make the childhood chickenpox vaccine. Merck is spending $1 billion to increase production and is building a new manufacturing plant in Durham, N.C. But it won’t be fully operational until 2013.

And even when the vaccine is more available, cost will remain a concern. At about $160 a dose, it is the most expensive adult vaccine.

 LILLY FOWLER

 

 

 

 

Print Print  

Like what we're doing? We'd appreciate your support.

Leave a comment